Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica

Grimes, 2002, Frequency of medical history items, drug interactions, and lifestyle characteristics that may interfere with antiretroviral medications, HIV Clin Trials, 3, 161, 10.1310/C1HV-Y1TA-RH80-B9K0

Kashuba, 2005, Drug-drug interactions and the pharmacotherapy of HIV infection, Top HIV Med, 13, 64

Amariles, 2007, Interacciones medicamentosas: aspectos generales y aproximación para establecer y utilizar su relevancia clínica, Med Clin (Barc), 129, 27, 10.1157/13106681

Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. October 10, 2006; 1-113. Available at: http://www.aidsinfo.nih.gov/Content-Files/AdultandAdolescentsGL.pdf (Accessed May 27 2007).

Krikorian, 2005, Drug-drug interactions and HIV therapy: What should pharmacists know?, J Pharm Pract, 18, 278, 10.1177/0897190005278504

Young, 2005, Review: Mixing new cocktails: Drug interactions in antiretroviral regimens, AIDS Patient Care STDS, 19, 286, 10.1089/apc.2005.19.286

Rathbun, 2002, Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement, Ann Pharmacother, 36, 702, 10.1345/aph.1A202

Acosta, 2002, Pharmacokinetic enhancement of protease inhibitors, J Acquir Immune Defic Syndr, 29, S11, 10.1097/00126334-200202011-00003

Zeldin, 2004, Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients, J Antimicrob Chemother, 53, 4, 10.1093/jac/dkh029

Nettles, 2006, Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring, Clin Infect Dis, 42, 1189, 10.1086/501458

Justesen, 2006, Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy, Basic Clin Pharmacol Toxicol, 98, 20, 10.1111/j.1742-7843.2006.pto_246.x

Wertheimer, 2006, Therapeutic drug monitoring in HIV treatment: A literature review, HIV Clin Trials, 7, 59, 10.1310/4CCJ-KT1T-H6PV-NLFC

Piscitelli, 2001, Interactions among drugs for HIV and opportunistic infections, N Engl J Med, 344, 984, 10.1056/NEJM200103293441307

Kashuba, 2005, Drug-drug interactions and the pharmacotherapy of HIV infection, Top HIV Med, 13, 64

Robertson, 2005, Drug interactions in the management of HIV infection, Expert Opin Pharmacother, 6, 233, 10.1517/14656566.6.2.233

Boffito, 2006, Practical perspectives on the use of tipranavir in combination with other medications: Lessons learned from pharmacokinetic studies, J Clin Pharmacol, 46, 130, 10.1177/0091270005283279

Tran, 2001, Delavirdine: Clinical pharmacokinetics and drug interactions, Clin Pharmacokinet, 40, 207, 10.2165/00003088-200140030-00005

DeSilva, 2001, Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine, AIDS, 15, 1281, 10.1097/00002030-200107060-00010

Winston, 2005, The management of HIV-1 protease inhibitor pharmacokinetic interactions, J Antimicrob Chemother, 56, 1, 10.1093/jac/dki184

Busti, 2004, Atazanavir for the treatment of human immunodeficiency virus infection, Pharmacotherapy, 24, 1732, 10.1592/phco.24.17.1732.52347

Hare, 2002, Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death, Clin Infect Dis, 35, e111, 10.1086/344179

Fichtenbaum, 2002, Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection, Clin Pharmacokinet, 41, 1195, 10.2165/00003088-200241140-00004

Fichtenbaum, 2002, Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047, AIDS, 16, 569, 10.1097/00002030-200203080-00008

Sax, 2006, Strategies for management and treatment of dyslipidemia in HIV/AIDS, AIDS Care, 18, 149, 10.1080/09540120500161843

Benesic, 2004, Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: Comparison of efficacy and interaction with indinavir, Infection, 32, 229, 10.1007/s15010-004-3136-7

Jacobson, 2004, Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors, Am J Cardiol, 94, 1140, 10.1016/j.amjcard.2004.07.080

Aberg, 2006, Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108, AIDS, 20, 725, 10.1097/01.aids.0000216373.53819.92

Sudano, 2006, Cardiovascular disease in HIV infection, Am Heart J, 151, 1147, 10.1016/j.ahj.2005.07.030

Bays, 2006, Statin safety: An overview and assessment of the data-2005, Am J Cardiol, 97, 6C, 10.1016/j.amjcard.2005.12.006

Cooper, 2003, Effect of itraconazole on the pharmacokinetics of rosuvastatin, Clin Pharmacol Ther, 73, 322, 10.1016/S0009-9236(02)17633-8

Wire, 2006, Fosamprenavir: Clinical pharmacokinetics and drug interactions of the amprenavir prodrug, Clin Pharmacokinet, 45, 137, 10.2165/00003088-200645020-00002

Arrington-Sanders, 2006, Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents, Pediatr Infect Dis J, 25, 1044, 10.1097/01.inf.0000242929.95258.69

Armstrong, 2003, Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, Part I, Psychosomatics, 44, 167, 10.1176/appi.psy.44.2.167

Armstrong, 2003, Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, Part II, Psychosomatics, 44, 515, 10.1176/appi.psy.44.6.515

von Moltke, 1998, Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: Relation to drug interactions in vivo, J Pharm Sci, 87, 1184, 10.1021/js980197h

Cvetkovic, 2003, Lopinavir/ritonavir: A review of its use in the management of HIV infection, Drugs, 63, 769, 10.2165/00003495-200363080-00004

Oldfield, 2006, Lopinavir/ritonavir: A review of its use in the management of HIV infection, Drugs, 66, 1275, 10.2165/00003495-200666090-00012

de Maat, 2003, Drug interactions between antiretroviral drugs and comedicated agents, Clin Pharmacokinet, 42, 223, 10.2165/00003088-200342030-00002

Currier, 2004, Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: A prospective study, Psychosomatics, 45, 210, 10.1176/appi.psy.45.3.210

Caballero, 2005, Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV, Ann Pharmacother, 39, 141, 10.1345/aph.1E248

Isbister, 2005, The pathophysiology of serotonin toxicity in animals and humans, Clin Neuropharmacol, 28, 205, 10.1097/01.wnf.0000177642.89888.85

Tseng, 1999, Significant interactions with new antiretrovirals and psychotropic drugs, Ann Pharmacother, 33, 461, 10.1345/aph.18240

Huang, 2001, Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors, Drug Metab Dispos, 29, 754

Taburet, 2004, Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus, Clin Pharmacol Ther, 75, 310, 10.1016/j.clpt.2003.12.013

Tran, 2002, Pharmacokinetic interaction between amprenavir and delavirdine: Evidence of induced clearance by amprenavir, Clin Pharmacol Ther, 72, 615, 10.1067/mcp.2002.128868

Kashuba, 2005, Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results, AIDS, 19, 145, 10.1097/00002030-200501280-00006

Mauss, 2004, A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir, HIV Med, 5, 15, 10.1111/j.1468-1293.2004.00179.x

Colombo, 2006, Ritonavir-boosted atazanavir-lopinavir combination: A pharmacokinetic interaction study of total, unbound plasma and cellular exposures, Antivir Ther, 11, 53, 10.1177/135965350601100112

Ribera, 2006, Atazanavir and lopinavir/ritonavir: Pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen, AIDS, 20, 1131, 10.1097/01.aids.0000226953.56976.ad

Ford, 2006, Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients, J Antimicrob Chemother, 58, 1009, 10.1093/jac/dkl379

Polk, 1999, Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men, Pharmacotherapy, 19, 1378, 10.1592/phco.19.18.1378.30905

Vourvahis, 2007, Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavirenhanced tipranavir, Pharmacotherapy, 27, 888, 10.1592/phco.27.6.888

Brophy, 2000, Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers, Antimicrob Agents Chemother, 44, 978, 10.1128/AAC.44.4.978-984.2000

Ray, 2004, Oral erythromycin and the risk of sudden death from cardiac causes, N Engl J Med, 351, 1089, 10.1056/NEJMoa040582

Jain, 2002, The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients, Liver Transpl, 8, 841, 10.1053/jlts.2002.34880

Vogel, 2004, Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients, Liver Transpl, 10, 939, 10.1002/lt.20165

Solas, 2004, Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor, Br J Clin Pharmacol, 57, 436, 10.1046/j.1365-2125.2003.02020.x

Dailly, 2005, Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz, Br J Clin Pharmacol, 60, 32, 10.1111/j.1365-2125.2005.02369.x

Bergshoeff, 2005, Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children, J Acquir Immune Defic Syndr, 39, 63, 10.1097/01.qai.0000155203.89350.85

Boffito, 2002, Pharmacokinetics of saquinavir co-administered with cimetidine, J Antimicrob Chemother, 50, 1081, 10.1093/jac/dkf232

Dailly, 2006, Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients, Eur J Clin Pharmacol, 62, 523, 10.1007/s00228-006-0122-2

Back, 2003, Pharmacokinetic drug interactions with nevirapine, J Acquir Immune Defic Syndr, 34, S8, 10.1097/00126334-200309011-00003

DeJesus, 2006, Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects, Antimicrob Agents Chemother, 50, 3157, 10.1128/AAC.00093-06

Gerber, 2005, Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS Clinical Trials Group 5108 Study, J Acquir Immune Defic Syndr, 39, 307, 10.1097/01.qai.0000167156.44980.33

Altice, 1999, Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone, AIDS, 13, 957, 10.1097/00002030-199905280-00012

Stocker, 2004, Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients, Antimicrob Agents Chemother, 48, 4148, 10.1128/AAC.48.11.4148-4153.2004

Bruce, 2006, Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice, J Acquir Immune Defic Syndr, 41, 563, 10.1097/01.qai.0000219769.89679.ec

Clarke, 2001, The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz, Br J Clin Pharmacol, 51, 213, 10.1046/j.1365-2125.2001.00342.x

Mildvan, 2002, Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women, J Acquir Immune Defic Syndr, 29, 471, 10.1097/00042560-200204150-00007

Saraga, 2006, Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient, Bipolar Disord, 8, 415, 10.1111/j.1399-5618.2006.00331.x

Ouellet, 1998, Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers, Br J Clin Pharmacol, 46, 111, 10.1046/j.1365-2125.1998.00749.x

Touzot, 2006, Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient, AIDS, 20, 1210, 10.1097/01.aids.0000226969.96880.3c

Van der Lee, 2006, Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects, Clin Pharmacol Ther, 80, 159, 10.1016/j.clpt.2006.04.014

Hogeland, 2007, Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects, Clin Pharmacol Ther, 81, 69, 10.1038/sj.clpt.6100027

Finch, 2002, Rifampin and rifabutin drug interactions: An update, Arch Intern Med, 162, 985, 10.1001/archinte.162.9.985

de Jong, 2004, Clinical management of tuberculosis in the context of HIV infection, Annu Rev Med, 55, 283, 10.1146/annurev.med.55.091902.103753

Aaron, 2004, Tuberculosis in HIV-infected patients: A comprehensive review, Clin Microbiol Infect, 10, 388, 10.1111/j.1469-0691.2004.00758.x

Spradling, 2002, Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: An institutional tuberculosis outbreak, Clin Infect Dis, 35, 1106, 10.1086/343047

Blumberg, 2003, American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis, Am J Respir Crit CareMed, 167, 603, 10.1164/rccm.167.4.603

Hamzeh, 2003, Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin, Clin Pharmacol Ther, 73, 159, 10.1067/mcp.2003.3

Kraft, 2004, Indinavir and rifabutin drug interactions in healthy volunteers, J Clin Pharmacol, 44, 305, 10.1177/0091270003262807

Rolla, 2006, Safety, efficacy and pharmacokinetics of ritonavir 400 mg/saquinavir 400 mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis, Clin Drug Investig, 26, 469, 10.2165/00044011-200626080-00005

Ribera, 2007, Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis, J Antimicrob Chemother, 59, 690, 10.1093/jac/dkl552

Benator, 2007, Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection, Pharmacotherapy, 27, 793, 10.1592/phco.27.6.793

Burger, 2006, Effect of rifampicin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers, Antimicrob Agents Chemother, 50, 3336, 10.1128/AAC.00461-06

Polk, 2001, Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males, Antimicrob Agents Chemother, 45, 502, 10.1128/AAC.45.2.502-508.2001

la Porte, 2004, Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers, Antimicrob Agents Chemother, 48, 1553, 10.1128/AAC.48.5.1553-1560.2004

Borin, 1997, Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate, Clin Pharmacol Ther, 61, 544, 10.1016/S0009-9236(97)90134-X

Ribera, 2001, Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis, J Acquir Immune Defic Syndr, 28, 450, 10.1097/00042560-200112150-00007

Ramachandran, 2006, Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration, J Acquir Immune Defic Syndr, 42, 36, 10.1097/01.qai.0000214808.75594.73

Matteelli, 2007, Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients, Curr HIV Res, 5, 349, 10.2174/157016207780636588

Manosuthi, 2005, Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin, AIDS, 19, 1481, 10.1097/01.aids.0000183630.27665.30

Manosuthi, 2006, Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results, AIDS, 20, 131, 10.1097/01.aids.0000196181.18916.9b

Friedland, 2006, Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV, J Antimicrob Chemother, 58, 1299, 10.1093/jac/dkl399

Brennan-Benson, 2005, Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: One size does not fit all, AIDS, 19, 1541, 10.1097/01.aids.0000183519.45137.a6

Matteelli, 2007, Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients, Curr HIV Res, 5, 349, 10.2174/157016207780636588

Weiner, 2005, Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis, Clin Infect Dis, 41, 1343, 10.1086/496980

Lim, 2004, Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction, J Acquir Immune Defic Syndr, 36, 1034, 10.1097/00126334-200408150-00006

Romanelli, 2003, Concurrent use of antiretrovirals and anticonvulsants in human immunodeficiency virus (HIV) seropositive patients, Curr Pharm Des, 9, 1433, 10.2174/1381612033454676

Mullin, 2004, Special populations: The management of seizures in HIV-positive patients, Curr Neurol Neurosci Rep, 4, 308, 10.1007/s11910-004-0057-x

Zhou, 2004, Pharmacokinetic interactions of drugs with St John's wort, J Psychopharmacol, 18, 262, 10.1177/0269881104042632

Izzo, 2004, Drug interactions with St. John's Wort (Hypericum perforatum): A review of the clinical evidence, Int J Clin Pharmacol Ther, 42, 139, 10.5414/CPP42139

Lee, 2006, Interactions between natural health products and antiretroviral drugs: Pharmacokinetic and pharmacodynamic effects, Clin Infect Dis, 43, 1052, 10.1086/507894

Tomilo, 2006, Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers, Pharmacotherapy, 26, 341, 10.1592/phco.26.3.341

Ford, 2005, Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir, Antimicrob Agents Chemother, 49, 467, 10.1128/AAC.49.1.467-469.2005

Damle, 2002, Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin, Antimicrob Agents Chemother, 46, 385, 10.1128/AAC.46.2.385-391.2002

Damle, 2002, Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole, Biopharm Drug Dispos, 23, 59, 10.1002/bdd.296

la Porte, 2005, Pharmacokinetic interaction study of indinavir/ ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers, J Clin Pharmacol, 45, 211, 10.1177/0091270004271063

Kearney, 2005, Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine, J Clin Pharmacol, 45, 1360, 10.1177/0091270005281351

Damle, 2002, Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads, J Clin Pharmacol, 42, 419, 10.1177/00912700222011472

Izzedine, 2004, Antiretroviral and immunosuppressive drug-drug interactions: An update, Kidney Int, 66, 532, 10.1111/j.1523-1755.2004.00772.x

Penzak, 2004, Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes, Ther Drug Monit, 26, 322, 10.1097/00007691-200406000-00018

Ding, 2004, Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers, Clin Pharmacol Ther, 76, 73, 10.1016/j.clpt.2004.02.008

Winston, 2006, Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers, AIDS, 20, 1401, 10.1097/01.aids.0000233573.41597.8a

Kakuda, 2006, Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers, Pharmacotherapy, 26, 1060, 10.1592/phco.26.8.1060

Amariles, 2007, Food consumption, cytochrome P450 3A4 (CYP3A4) presystemic inhibitors, and bioavailability of saquinavir, Farm Hosp, 31, 68, 10.1016/S1130-6343(07)75713-6

Ray, 2005, Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase, AIDS Rev, 7, 113

Hoggard, 2001, Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo, Antimicrob Agents Chemother, 45, 577, 10.1128/AAC.45.2.577-582.2001

Havlir, 2000, In vivo antagonism with zidovudine plus stavudine combination therapy, J Infect Dis, 182, 321, 10.1086/315683

Becher, 2004, Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients, AIDS, 18, 181, 10.1097/00002030-200401230-00006

Boubaker, 2001, Hyperlactatemia and antiretroviral therapy: The Swiss HIV Cohort Study, Clin Infect Dis, 33, 1931, 10.1086/324353

Coghlan, 2001, Symptomatic lactic acidosis in hospitalized antiretroviraltreated patients with human immunodeficiency virus infection: A report of 12 cases, Clin Infect Dis, 33, 1914, 10.1086/323783

Catanzaro, 2004, Drug interactions with antiretrovirals, Curr Infect Dis Rep, 1, 89

Dalakas, 2001, Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2’3’dideoxycytidine (ddC), Lab Invest, 81, 1537, 10.1038/labinvest.3780367

Simpson, 1995, Nucleoside analogue associated peripheral neuropathy in human immunodeficiency virus infection, J Acquir Immune Defic Syndr Hum Retrovirol, 9, 153

Dagan, 2002, Mitochondrial dysfunction and antiretroviral nucleoside analogue toxicities: What is the evidence?, Mitochondrion, 1, 397, 10.1016/S1567-7249(02)00003-X

Petit, 2005, Mitochondria are sensors for HIV drugs, Trends Pharmacol Sci, 26, 258, 10.1016/j.tips.2005.03.006

Hochster, 1990, Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study, Ann Intern Med, 113, 111, 10.7326/0003-4819-113-2-111

Fleischer, 2004, Nucleoside analogues and mitochondrial toxicity, Clin Infect Dis, 38, e79, 10.1086/383151

Perronne, 2006, Antiviral hepatitis and antiretroviral drug interactions, J Hepatol, 44, S119, 10.1016/j.jhep.2005.11.025

Steele, 1991, Toxic hepatitis with isoniazide and rifampin: A meta-analysis, Chest, 99, 465, 10.1378/chest.99.2.465

Yee, 2003, Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis, Am J Respir Crit Care Med, 167, 1472, 10.1164/rccm.200206-626OC

Shriner, 1992, Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine, Am J Med, 93, 94, 10.1016/0002-9343(92)90687-7

Fisher, 1989, Risk factors for amphotericin B-associated nephrotoxicity, Am J Med, 87, 547, 10.1016/S0002-9343(89)80612-6

Antiviral briefs: Pregnancy category change for efavirenz. AIDS Patient Care STDS 2005; 19:413.

Amariles P, Lacampa P, Sáez-Benito L. Dosage adjustments for hepatic dysfunction. Am J Health-System Pharm 2008; 65 (in press).

Kiang, 2005, UDP-glucuronosyltransferases and clinical drug-drug interactions, Pharmacol Ther, 106, 97, 10.1016/j.pharmthera.2004.10.013

Gallicano, 1999, Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients, Br J Clin Pharmacol, 48, 168, 10.1046/j.1365-2125.1999.00987.x

Martinez, 2004, Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults, Lancet, 364, 65, 10.1016/S0140-6736(04)16591-4

Ray, 2004, Role of purine nucleoside phosphorylase in interactions between 2’,3’-dideoxyinosine and allopurinol, ganciclovir, or tenofovir, Antimicrob Agents Chemother, 48, 1089, 10.1128/AAC.48.4.1089-1095.2004

Antoniou, 2003, Tenofovir: A nucleotide analog for the management of human immunodeficiency virus infection, Pharmacotherapy, 23, 29, 10.1592/phco.23.1.29.31915

Guo, 2004, Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate, Pharmacotherapy, 24, 1089, 10.1592/phco.24.11.1089.36138

Masía, 2005, Severe toxicity associated with the combination of tenofovir and didanosine: Case report and review, Int J STD AIDS, 16, 646, 10.1258/0956462054944480

Tseng, 2007, CD4+ cell count decline despite HIV suppression: A probable didanosine-valganciclovir interaction, Ann Pharmacother, 41, 512, 10.1345/aph.1H472

Barreiro, 2006, Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir, J Antimicrob Chemother, 57, 806, 10.1093/jac/dkl045

Anderson, 2006, Comment on: Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir, J Antimicrob Chemother, 58, 220, 10.1093/jac/dkl203

Taburet, 2004, Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients, Antimicrob Agents Chemother, 48, 2091, 10.1128/AAC.48.6.2091-2096.2004

Boffito, 2005, Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate, Antimicrob Agents Chemother, 49, 4386, 10.1128/AAC.49.10.4386-4389.2005

Droste, 2006, Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients, J Acquir Immune Defic Syndr, 41, 37, 10.1097/01.qai.0000191997.70034.80

Droste, 2005, Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers, Antimicrob Agents Chemother, 49, 680, 10.1128/AAC.49.2.680-684.2005

Heck, 2000, Potential interactions between alternative therapies and warfarin, Am J Health Syst Pharm, 57, 1221, 10.1093/ajhp/57.13.1221

Amsay, 2005, Complimentary and alternative medicine use among patients starting warfarin, Br J Haematol, 130, 777, 10.1111/j.1365-2141.2005.05689.x

Lin, 2003, Role of P-glycoprotein in pharmacokinetics: Clinical implications, Clin Pharmacokinet, 42, 59, 10.2165/00003088-200342010-00003

Lin, 2003, Drug-drug interaction mediated by inhibition and induction of P-glycoprotein, Adv Drug Deliv Rev, 55, 53, 10.1016/S0169-409X(02)00171-0

Khaliq, 2000, Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus, Clin Pharmacol Ther, 68, 637, 10.1067/mcp.2000.112363

Oette, 2005, Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients, J Antimicrob Chemother, 56, 416, 10.1093/jac/dki234

Fellay, 2005, Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients, Eur J Clin Pharmacol, 60, 865, 10.1007/s00228-004-0855-8

Mouly, 2006, Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients, Br J Clin Pharmacol, 62, 200, 10.1111/j.1365-2125.2006.02637.x

Hulgan, 2005, Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons, J Acquir Immune Defic Syndr, 38, 277